Skip to main content
PMC home page
BMC Cardiovascular Disorders logoLink to BMC Cardiovascular Disorders
. 2005 Jun 2;5:12. doi: 10.1186/1471-2261-5-12

A systematic review of intravenous gamma globulin for therapy of acute myocarditis

Joan L Robinson 1,✉, Lisa Hartling 2, Ellen Crumley 1,2, Ben Vandermeer 1,2, Terry P Klassen 1,2
PMCID: PMC1173096  PMID: 15932639

Abstract

Background

Intravenous gamma globulin (IVGG) is commonly used in the management of acute myocarditis. The objective of this study was to systematically review the literature evaluating this practice.

Methods

We conducted a comprehensive search (electronic databases, trials registries, conference proceedings, reference lists, contact with authors) to identify studies evaluating the use of IVGG in adults and children with a clinical or histologically proven diagnosis of myocarditis of possible viral etiology and symptoms of less than six months duration. Two reviewers independently screened the searches, applied inclusion criteria, and graded the evidence.

Results

Results were described qualitatively; data were not pooled because only one randomized controlled trial (RCT) with 62 patients was identified. The RCT showed no benefit with respect to cardiac function, functional outcome, or event-free survival. A small, uncontrolled trial (n = 10) showed significant improvement in LVEF from a mean of 24% to 41% 12 months after IVGG in nine survivors. A retrospective cohort study of pediatric patients showed improvement in cardiac function and a trend towards improved survival in patients receiving IVGG (n = 21) versus historic controls (n = 25). Ten case reports and two case series (total n = 21) described improvement in cardiac function after administration of IVGG; two case reports showed no benefit of IVGG. One case of hemolytic anemia was attributed to IVGG.

Conclusion

There is insufficient data from methodologically strong studies to recommend routine use of IVGG for acute myocarditis. Future randomized studies that take into account the etiology of acute myocarditis will be required to determine the efficacy of IVGG.

Background

Myocarditis is an inflammatory cardiomyopathy that occurs in all age groups [1]. Most cases are thought to be sub-clinical, but myocarditis can manifest as fulminant or chronic heart failure [2]. The inflammation is presumed to most commonly start as an infectious process, although autoimmune and idiopathic forms also occur [1]. Bacterial or protozoal myocarditis is rare in the developed world, with the vast majority of cases being viral [3]. Although most viruses that are pathogenic for humans can cause myocarditis, common etiologic agents are enteroviruses and adenoviruses [4]. It remains unclear if the primary problem in severe disease is ongoing damage from a virus, a post-infectious inflammatory reaction, or a combination of both factors. If ongoing infection is the primary problem, IVGG could be efficacious if it contains antibodies to the microbe. IVGG also has anti-inflammatory properties that prevent the formation of and downregulate cytokines [5] so could be efficacious even if the primary problem is a post-infectious inflammatory reaction.

The objective of this study was to review the evidence evaluating the use of IVGG in the treatment of patients with acute myocarditis. A secondary objective was to determine if there is an identifiable group of acute myocarditis patients (based on age, duration of symptoms, acuity of onset of symptoms, cardiac function at presentation, virologic results, or the presence or absence of histologic evidence of acute myocarditis on cardiac biopsy in patients where a biopsy was performed) who would benefit from IVGG. The review of randomized controlled trials has been registered with the Cochrane Collaboration and regular updates will be available in the Cochrane Library.

Methods

Searching

We systematically searched the following electronic databases: Cochrane Central Register of Controlled Trials (4th quarter, 2004), MEDLINE (1966 to January Week 4, 2005), EMBASE (1988 to Week 6, 2005), CINAHL (1982 to January Week 3, 2005), Web of Science (1975 to February 5, 2005), and several trial registries in addition to the Cochrane Heart Group's Trial Registry [6-11]. A comprehensive search strategy was developed by a medical research librarian based on the following terms: immunoglobulin, gammaglobulin, ivig, immunoglobulin, igg, immune, serum, myocarditis, cardiomyopathy, myocardiopathy, carditis, heart, inflammation. The complete search strategy is available from the authors on request. We also contacted the primary author of the RCT, and reviewed the reference lists of all selected articles. In addition, we handsearched proceedings from the following meetings for RCTs: American Heart Association (1999–2004), American College of Cardiology (1998–2005), European Society of Cardiology (1998–2004), and International Heart and Lung Transplantation Society (1998–2004). The search was not limited by language or publication status.

Study selection

Two reviewers independently screened the searches for potentially relevant studies. The full manuscript of all potentially relevant studies was retrieved and each study was assessed independently by two reviewers for inclusion using predetermined eligibility criteria. Primary studies of any design were eligible for inclusion. Inclusion criteria included reports of patients given IVGG for possible viral myocarditis within six months of onset of symptoms. Because of the poor sensitivity of cardiac biopsy as a diagnostic tool for acute myocarditis, a histologic diagnosis was not required. Exclusion criteria included reports of patients with evidence of ischemic heart disease, rheumatic heart disease, or any other non-viral etiology, onset of myocarditis less than six months postpartum (as the pathogenesis of postpartum myocarditis may differ from that of presumed viral myocarditis), or receipt of immunosuppressive therapy (unless this was not possible as they were reported as part of a case series). Reports of use of high-dose immunoglobulin directed at specific organisms were excluded as efficacy may be influenced by the formulation available and the accuracy of the etiologic diagnosis.

Assessment of methodological quality

Study quality was assessed independently by two reviewers and discrepancies were resolved by consensus. RCTs were evaluated using the previously validated Jadad 5-point score to assess randomization, double blinding, and losses to follow-up [12]. Allocation concealment was assessed as adequate, inadequate, or unclear [13]. Non-RCTs were graded according to the levels of evidence presented in Table 1.

Table 1.

Levels of evidence for studies of therapeutic interventions from the Oxford Centre for Evidence-based Medicine (website title http://www.cebm.net/levels_of_evidence.asp) [14]

Level Study design
1 A Systematic review (with homogeneity) of randomized controlled trials
B Individual randomized controlled trial (with narrow confidence interval)
C All or none
2 A Systematic review (with homogeneity) of cohort studies
B Individual cohort study (including low quality randomized controlled trial, e.g., < 80% follow-up)
C "Outcomes" research; ecological studies
3 A Systematic review (with homogeneity) of case-control studies
B Individual case-control study
4 Case series (and poor quality cohort and case-control studies)
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"
Open in a new tab

Data extraction

Data were extracted by one reviewer using a standard form and checked for accuracy and completeness by a second. The primary outcome was rate of survival without a transplant or requirement for placement of a left ventricular assist device. Secondary outcomes included change in echocardiographic measures of cardiac function, duration of hospitalization, and improvement in functional symptoms (determined by increased exercise tolerance as measured by any objective test and New York Heart Association Functional Capacity) when available. Data were collected on complications and adverse events.

Data analysis

Data from studies that were not RCTs were reported but not analyzed further. We planned to combine data from RCTs, to do sub-group analyses, and to test for publication bias, however these were not possible as only one RCT was identified. For the RCT, dichotomous data on efficacy (e.g. event-free survival) were expressed as an odds ratio (OR) with 95% confidence interval. Dichotomous data on adverse events were reported as a risk difference and number needed to harm with 95% confidence intervals. Continuous data (change in left ventricular ejection fraction and peak oxygen consumption) were converted to the mean difference with 95% confidence intervals. For peak oxygen consumption, we assumed a correlation of 0.5 and used the methods of Follmann [15] to calculate the standard deviations of the change from baseline estimates. Since the number per group was not given for this variable, an estimate of the sample size in each group had to be estimated by pro-rating the original group sample sizes to the new total sample size.

Results

Figure 1 presents a flow diagram of studies considered for inclusion in the review. Only one RCT evaluating IVGG for acute myocarditis has been reported to date [16]. The trial was of moderate methodological quality according to the Jadad scale (3 out of maximum 5 points, where 5 indicates highest quality); allocation concealment was unclear. The study enrolled 62 adults (mean age 43.0 +/- 12.3 years; 37 men), of which only ten had cellular inflammation on endomyocardial biopsy (four fulfilled the Dallas criteria for acute myocarditis, and three for borderline myocarditis). The authors reported that the given sample size would provide 80% power to detect a difference between groups of ≥ 8% in ejection fraction (EF) change scores. Patients were randomized to receive either 2 g/kg IVGG or an equivalent volume of 0.1% albumin in a blinded fashion. The incidence of death or requirement for cardiac transplant or placement of a left ventricular assist device was low in both groups. Event-free survival was not significantly different but favored the control group (OR 0.52, 95% CI 0.12, 2.30). Follow-up at 6 and 12 months showed no significant difference in improvement in left ventricular ejection fraction for cases and controls (mean difference 0.00, 95% CI -0.07, 0.07 at six months; 0.01, 95% CI -0.06, 0.08 at 12 months). Functional capacity as assessed by peak oxygen consumption was not significantly different in the two groups at 12 months (mean difference -0.80, 95% CI -4.57, 2.97). Infusion-related side effects occurred significantly more often in the treated group (RD 0.33, 95% CI 0.17, 0.50; number needed to harm = 3, 95% CI 2, 6), but all appeared to be mild.

Figure 1.

Figure 1

Open in a new tab

Flow diagram of studies considered for inclusion in the review

Sixteen additional studies of various designs met the inclusion criteria [see Additional file 1]. These included a retrospective case series [17], an uncontrolled trial [18], two case series [5,19], and twelve case reports [20-31]. In a retrospective cohort study, Drucker compared children who were treated with IVGG (n = 21) to historic controls (n = 26); 65% of the sample was less than two years of age [17]. The treatment group showed improved cardiac function and a trend (though not statistically significant) towards improved survival. McNamara conducted an uncontrolled trial involving 10 adults (mean age 35.8 +/- 15 years) [18]. One patient with refractory arrhythmias and severe heart failure died during the infusion; the other nine patients showed an impressive improvement in cardiac function following administration of IVGG, with a significant increase in left ventricular ejection fraction at 12-month follow-up (p = 0.008). In ten case reports and both case series, improvement in cardiac function was described after use of IVGG in a total of 21 cases, although improvement was considered to be minimal in one case [26]. In the other two case reports, there was no benefit of IVGG in a patient presenting with hand, foot and mouth disease and acute myocarditis from coxsackievirus A16 [27] and in a patient with fulminant myocarditis of unclear etiology [28]. Hemolytic anemia was attributed to use of IVGG in one case report [26].

We could find no ongoing trials of the use of IVGG in acute myocarditis, although the European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID) is evaluating hyperimmunoglobulin for patients with cytomegalovirus-positive myocarditis [32].

Discussion

The small number of studies evaluating IVGG in the treatment of acute myocarditis reflects the immature state of this body of literature. We identified only one RCT (Level 1 evidence), which involved 62 adult patients with idiopathic cardiomyopathy (of which only 10 had histologic evidence of myocarditis) and showed no apparent benefit [9]. This is in contrast to an uncontrolled trial and numerous observational studies (Level 4 evidence), most of which suggested potential benefit. This indicates a possible bias towards publication of case reports or case series with positive results. The validity of evidence was generally poor, with the majority of included studies ranking low in terms of level of evidence. The most important threat to validity for fifteen of the seventeen included studies was the lack of controls, which could result in an overestimate of the benefit of IVGG. Spontaneous improvement in cardiac function is common with acute myocarditis and can be rapid or gradual, so it is possible that the improvement noted in these cases was part of the natural history of the disease. The retrospective cohort study demonstrated a greater improvement in cardiac function in patients given IVGG compared to historic controls [17]; this type of study is more susceptible to bias because of the inability to fully control for all potential confounders, such as other changes in patient management over the eight-year study period.

Acute myocarditis is a relatively non-specific entity, as the diagnosis is often clinical. Laboratory confirmation consists of microbiologic, histologic, and immunohistochemical methods. With regard to microbiologic confirmation, it is rare to isolate the etiologic agent from a myocardial biopsy (probably because the biopsy is usually done too late in the course of the illness), and identification of organisms by molecular techniques is in its infancy [4]. However, with the development of new effective antivirals, there should be increased efforts towards making a virologic diagnosis early in the course of myocarditis as it is possible that antivirals would improve the prognosis. Furthermore, there are case reports of hyperimmunoglobulin showing an apparent effect in cases of varicella [33], cytomegalovirus [34], and parvovirus [35] myocarditis. With regard to histologic confirmation, the Dallas criteria (lymphocyte infiltration with myocyte necrosis) [36] and more recently the World Heart Federation criteria (>14 leukocytes/mm2 with necrosis or degeneration) [37] have been used for histologic diagnosis, but the sensitivity and specificity of these criteria are not known. There are no standardized values for immunohistochemical markers [38]. Our aim in this study was to analyze reports of use of IVGG for presumed viral myocarditis, but it is possible that many of the patients in the reports did not have viral myocarditis (only 10 of the 62 patients in the RTC had cellular inflammation on endomyocardial biopsy). Once our ability to accurately diagnose viral myocarditis improves, it may be possible to identify a subset of patients who will respond to IVGG. This might be patients whose disease was precipitated by a specific virus, or patients who are treated with IVGG early in the course of their illness when they have ongoing viral replication in the myocardium. Perhaps pediatric patients are more likely to respond. Children are thought to be more likely to present in the acute inflammatory stage of illness [16], and may have a worse prognosis than do adults when they present with fulminant myocarditis [39,40]

In conclusion, the value of IVGG in patients with acute myocarditis is obscured by the poor quality of evidence. We were not able to identify a subgroup of patients who appear to be more likely to respond to IVGG. A large RCT is required to evaluate the efficacy of IVGG for acute myocarditis with emphasis on the etiology of the myocarditis. Until there are RCTs demonstrating benefit, use of IVGG for acute myocarditis should not be part of routine practice. Moreover, there is a great need for further studies of the pathophysiology of acute myocarditis, which would allow for a better understanding of the etiology and the natural history of the disease. This might allow for improved diagnostic criteria, which would make it much easier to design studies of treatment options. This may also assist in identifying sub-groups of patients where IVGG or other therapies have a greater potential to confer clinical benefit.

List of abbreviations

IVGG – intravenous gamma globulin

RCT – Randomized controlled trial

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

The idea for the study originated with JLR. The protocol was written by LH with help from JLR and EC. The literature review was completed by EC, and LH and JLR reviewed the papers and derived the data. Statistical analysis was done by BV. The manuscript was written by JLR and LH with input from TPK, EC and BV.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2261/5/12/prepub

Supplementary Material

Additional File 1

Observational studies and nonrandomized trials examining the use of IVGG in acute myocarditis. This table summarizes all studies reporting the use of IVGG for acute myocarditis.

Click here for file (64.5KB, doc)

Acknowledgments

Acknowledgements

We thank Philip Berry and Marilyn Josefsson, from the Alberta Research Centre for Child Health Evidence, for administrative support and collection of articles.

Contributor Information

Joan L Robinson, Email: jr3@ualberta.ca.

Lisa Hartling, Email: hartling@ualberta.ca.

Ellen Crumley, Email: ecrumley@ualberta.ca.

Ben Vandermeer, Email: bv1@ualberta.ca.

Terry P Klassen, Email: terry.klassen@ualberta.ca.

References

  1. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996;93:841–2. doi: 10.1161/01.cir.93.5.841. [DOI] [PubMed] [Google Scholar]
  2. Levi D, Alejoes J. Diagnosis and treatment of pediatric viral myocarditis. Curr Opin Cardiol. 2001;16:77–83. doi: 10.1097/00001573-200103000-00001. [DOI] [PubMed] [Google Scholar]
  3. Towbin JA. Myocarditis and pericarditis in adolescents. Adolesc Med. 2001;12:47–67. [PubMed] [Google Scholar]
  4. Martin AB, Webber S, Fricker FJ, Jaffe R, Demmler G, Kearney D, Zhang YH, Bodurtha J, Gelb B, Ni J. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation. 1994;90:330–9. doi: 10.1161/01.cir.90.1.330. [DOI] [PubMed] [Google Scholar]
  5. Kishimoto C, Shioji K, Kinoshita M, Iwase T, Tamaki S, Fujii M, Murashige A, Maruhashi H, Takeda S, Nonogi H, Hashimoto T. Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress. Intern J Cardiol. 2003;91:173–8. doi: 10.1016/S0167-5273(03)00002-0. [DOI] [PubMed] [Google Scholar]
  6. Pubmed http://www.nhlbi.nih.gov/index.htm
  7. Curren Controlled Trials http://www.controlled-trials.com/, clinicaltrials.gov
  8. The National Research Register http://www.update-software.com/National/
  9. Center Watch Clinical Trials Listing Site http://www.centerwatch.com/search.asp
  10. Cardiosource http://www.cardiosource.com
  11. New England Research Institutes Pediatric Cardiomyopathy Registry http://www.neri.org/html/research/clinical/pediatric.asp
  12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized controlled trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. doi: 10.1016/0197-2456(95)00134-4. [DOI] [PubMed] [Google Scholar]
  13. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:403–412. doi: 10.1001/jama.273.5.408. [DOI] [PubMed] [Google Scholar]
  14. Centre for Evidence-Based Medicine http://www.cebm.net/levels_of_evidence.asp
  15. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous variables. J Clin Epidemiol. 1992;45:769–73. doi: 10.1016/0895-4356(92)90054-Q. [DOI] [PubMed] [Google Scholar]
  16. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254–9. doi: 10.1161/01.cir.103.18.2254. [DOI] [PubMed] [Google Scholar]
  17. Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, Baker AL, Perez-Atayde AR, Newburger JW. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89:252–7. doi: 10.1161/01.cir.89.1.252. [DOI] [PubMed] [Google Scholar]
  18. McNamara DM, Rosenblum WD, Janosko KM, Trost MK, Villaneuva FS, Demetris AJ, Murali S, Feldman AM. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation. 1997;95:2476–8. doi: 10.1161/01.cir.95.11.2476. [DOI] [PubMed] [Google Scholar]
  19. Wang CY, Li Lu F, Wu MH, Lee CY, Huang LM. Fatal coxsackievirus A16 infection. Pediatr Infect Dis J. 2004;23:275–6. doi: 10.1097/01.inf.0000115950.63906.78. [DOI] [PubMed] [Google Scholar]
  20. Takeda Y, Yasuda S, Miyazaki S, Daikoku S, Nakatani S, Nonogi H. High-dose immunoglobulin G therapy for fulminant myocarditis. Jap Circ J. 1998;62:871–2. doi: 10.1253/jcj.62.871. [DOI] [PubMed] [Google Scholar]
  21. Nigro G, Bastianon V, Colloridi V, Ventriglia F, Gallo P, D'Amati G, Koch WC, Adler SP. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis. 2000;31:65–9. doi: 10.1086/313929. [DOI] [PubMed] [Google Scholar]
  22. Tsai YG, Ou TY, Wang CC, Tsai MC, Yuh YS, Hwang B. Intravenous gamma-globulin therapy in myocarditis complicated with complete heart block: report of one case. Acta Paediatr Taiwan. 2001;42:311–3. [PubMed] [Google Scholar]
  23. Shioji K, Matsuura Y, Iwase T, Kitaguchi S, Nakamura H, Yodoi J, Hashimoto T, Kawai C, Kishimoto C. Successful immunoglobulin treatment for fulminant myocarditis and serial analysis of serum thiredoxin – a case report. Circulation Journal. 2002;66:977–80. doi: 10.1253/circj.66.977. [DOI] [PubMed] [Google Scholar]
  24. Tedeschi A, Airaghi L, Giannini S, Ciceri L, Massari FM. High-dose intravenous immunoglobulin in the treatment of acute myocarditis. A case report and review of the literature. J Intern Med. 2002;251:169–73. doi: 10.1046/j.1365-2796.2002.00929.x. [DOI] [PubMed] [Google Scholar]
  25. Stouffer GA, Sheahan RG, Lenihan DJ, Patel P, Lenihan DJ. The current status of immune modulating therapy for myocarditis: a case of acute parvovirus myocarditis treated with intravenous immunoglobulin. Am J Med Sci. pp. 369–74. [DOI] [PubMed]
  26. Karaaslan S, Oran B, Caliskan U, Baysal T, Baspinar O, Tas A. Hemolysis after administration of high-dose immunoglobulin in a patient with myocarditis. Turk J Haematol. 2003;20:237–40. [PubMed] [Google Scholar]
  27. Khan MA, Das B, Lohe A, Sharma J. Neonatal myocarditis presenting as an apparent life threatening event. Clin Pediatr (Phila) 2003;42:649–52. doi: 10.1177/000992280304200713. [DOI] [PubMed] [Google Scholar]
  28. Kim HS, Sohn S, Park JY, Seo JW. Fulminant myocarditis successfully treated with high-dose immunoglobulin. Int J Cardiol. 2004;96:485–6. doi: 10.1016/j.ijcard.2003.05.037. [DOI] [PubMed] [Google Scholar]
  29. Braun JP, Schneider M, Dohmen P, Dopfmer U. Successful treatment of dilative cardiomyopathy in a 12-year-old girl using the calcium sensitizer levosimendan after weaning from mechanical biventricular assist support. J Cardiothorac Vasc Anest. 2004;18:772–4. doi: 10.1053/j.jvca.2004.08.020. [DOI] [PubMed] [Google Scholar]
  30. Abe S, Okura Y, Hoyano M, Kazama R, Watanabe S, Ozawa T, Saigawa T, Hayashi M, Yoshida T, Tachikawa H, Kashimura T, Suzuki K, Nagahashi M, Watanabe J, Shimada K, Hasegawa G, Kato K, Hanawa H, Kodama M, Aizawa Y. Plasma concentrations of cytokines and neurohumoral factors in a case of fulminant myocarditis successfully treated with intravenous immunoglobulin and percutaneous cardiopulmonary support. Circ J. 2004;68:1223–6. doi: 10.1253/circj.68.1223. [DOI] [PubMed] [Google Scholar]
  31. English RF, Janosly JE, Ettedgui JA, Webber SA. Outcomes for children with acute myocarditis. Cardiol Young. 2004;14:488–93. doi: 10.1017/S1047951104005049. [DOI] [PubMed] [Google Scholar]
  32. Maisch B, Hufnagel G, Schonian U, Hengstenberg C. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID) Eur Heart J. 1995;16:173–5. doi: 10.1093/eurheartj/16.suppl_o.173. [DOI] [PubMed] [Google Scholar]
  33. Alter P, Grimm W, Maisch B. Varicella myocarditis in an adult. Heart. 2001;85:e2. doi: 10.1136/heart.85.1.e2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Maisch B, Pankuweit S, Funck R, Koelsch S. Effective CMV hyperimmunoglobulin treatment in CMV myocarditis – a controlled treatment trial (Abstract #674) Proceedings of the European Society of Cardiology Annual Meeting: 28 Aug – 1 Sept 2004; Munich.
  35. Pankuweit S, Lamparter S, Funck R, Maisch B. Endomyocardial biopsy-guided diagnosis and treatment of inflammatory cardiomyopathies. Dtsch Med Wochenschr. 2004;129:2169–72. doi: 10.1055/s-2004-831860. [DOI] [PubMed] [Google Scholar]
  36. Aretz HT. Myocarditis: the Dallas criteria. Human Pathol. 1987;18:619–24. doi: 10.1016/s0046-8177(87)80363-5. [DOI] [PubMed] [Google Scholar]
  37. Maisch B, Ristic AD, Hufnagel G, Funck R, Alter P, Tontsch D, Pankuweit S. Dilated cardiomyopathies as a cause of congestive heart failure. Herz. 2002;27:113–34. doi: 10.1007/s00059-002-2373-8. [DOI] [PubMed] [Google Scholar]
  38. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, Zembala M, Polonski L, Rozek MM, Wodniecki J. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Two-year follow-up results. Circulation. 2001;104:39–45. doi: 10.1161/01.cir.104.1.39. [DOI] [PubMed] [Google Scholar]
  39. McCarthy RE, 3rd, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, Baughman KL. Long-term outcome of fulminant myocarditis as compared with acute (non-fulminant) myocarditis. New Engl J Med. 2000;342:690–5. doi: 10.1056/NEJM200003093421003. [DOI] [PubMed] [Google Scholar]
  40. Mounts AW, Amr S, Jamshidi R, Groves C, Dwyer D, Guarner J, Dawson JE, Oberste MS, Parashar U, Spevak P, Alexander J. A cluster of fulminant myocarditis cases in children, Baltimore, Maryland, 1997. Pediatr Cardiol. 2001;22:34–9. doi: 10.1007/s002460010148. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Additional File 1

Observational studies and nonrandomized trials examining the use of IVGG in acute myocarditis. This table summarizes all studies reporting the use of IVGG for acute myocarditis.

Click here for file (64.5KB, doc)

Articles from BMC Cardiovascular Disorders are provided here courtesy of BMC

RESOURCES